Updated October 2026. This guide now reflects FDA's April 2026 change and the July 2026 advisory committee vote. Compounding Finder does not currently route BPC-157 quote requests; see our BPC-157 legal and safety notes.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a peptide consisting of 15 amino acids derived from a protein found in human gastric juice. It has been studied in animal models for its effects on tissue healing, inflammation, and gut health, and has gained significant interest among patients and integrative medicine practitioners.
BPC-157 is not FDA-approved for any use, and no drug company makes a commercial version.
What Is BPC-157 Used For?
While large-scale human clinical trials are limited, providers have prescribed BPC-157 for a range of conditions based on preclinical research and clinical experience. Common uses include:
- Musculoskeletal injuries — tendon, ligament, and muscle healing
- Gut health — intestinal inflammation, leaky gut, inflammatory bowel conditions
- Joint pain — osteoarthritis and joint degeneration support
- Post-surgical recovery — supporting tissue repair after surgery
- Neuroprotection — some providers have used it for peripheral nerve healing
It is important to understand that BPC-157's evidence base comes primarily from animal studies. Many patients and providers report positive results, but that is not the same as controlled human trials, and the peptide has not been FDA-approved for any specific indication.
Forms Patients Ask About
Compounding pharmacies have prepared BPC-157 in three forms:
- Injectable (subcutaneous) — usually a freeze-dried powder in a vial, mixed with bacteriostatic water before injection
- Oral capsules — mostly for gut-related goals; the peptide has shown stability in stomach acid in studies
- Topical cream — for localized use on an injured area; less common
Where BPC-157 Stands With the FDA
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may only compound from a bulk ingredient that is part of an FDA-approved drug, has a USP or NF monograph, or is on FDA's 503A bulk drug substances list. BPC-157 meets none of these.
- Late 2023: Category 2. FDA placed BPC-157 in Category 2, its list of bulk substances that may present significant safety risks.
- April 2026: out of Category 2, but not compoundable. FDA took BPC-157 off the Category 2 list; it now appears among nominations that were withdrawn. That did not add it to the 503A list, and BPC-157 is not in Category 1, the substances FDA does not object to pharmacies using while it evaluates them.
- July 23, 2026: an advisory vote. FDA's Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding BPC-157 to the 503A list. At the same meeting it also recommended KPV, TB-500, MOTS-c, Epitalon, and Semax. FDA's own reviewers had recommended against all of them.
The committee only advises FDA. Adding a substance to the list takes FDA rulemaking, and as of October 2026 FDA has not proposed it. Until it does, US compounding pharmacies have no clear legal pathway to prepare BPC-157, with or without a prescription.
Safety Considerations
What FDA Has Said
FDA has said it found little or no safety information for the proposed routes of use, and that BPC-157 may carry a risk of immune reactions by some routes and may raise problems with peptide-related impurities.
Reported Side Effects
Side effects reported in preclinical data and clinical reports are mostly mild and include:
- Injection site redness or irritation
- Mild nausea (oral form)
- Dizziness (rare)
The absence of large human trials means the long-term safety profile is not established.
Research-Peptide Sellers
BPC-157 is widely sold online as a "research peptide" labeled not for human use. These sellers operate outside FDA and state pharmacy oversight, and their products may be underdosed, contaminated, or mislabeled. Injectable products carry the most risk, because sterility is not verified.
Athletes
BPC-157 is prohibited by the World Anti-Doping Agency (WADA). Competitive athletes should not use it.
Can I Get BPC-157 Through Compounding Finder?
Not at this time. Because BPC-157 is not on the 503A list, Compounding Finder does not send BPC-157 requests to pharmacies. We will update our BPC-157 page if FDA acts.
If BPC-157 was suggested to you, talk to your prescriber about the condition you want treated and the FDA-approved options for it.
We Do Not Currently Route BPC-157 Quote Requests
BPC-157 is not on the FDA 503A bulk drug substances list. An FDA advisory committee voted in July 2026 to recommend adding it, but FDA has not acted, so US compounding pharmacies have no clear legal pathway to prepare it and Compounding Finder is not sending BPC-157 quote requests to pharmacies. If FDA guidance changes, we will revisit.